Loading…
← CockpitCompetitor Analysis › 6185.HK CanSino Biologics, Inc. Class HOpen in the cockpit ↗

CanSino Biologics, Inc. Class H6185.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology

Chinese vaccine maker using viral-vector technology, known for its COVID-19 vaccine and meningitis/rabies/Ebola vaccines.

≈ China's viral-vector vaccine playerMomentum neutral 42
Mkt cap
$1.36B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$10.5M
20-day average traded
Fwd P/E
60.5×
forward earnings
ROIC−WACC
-7.2 pp
WACC 9.0%
Hurdle
n/a
no reverse DCF
Next earnings
132 days
30 Mar 2027
Close · HKDHK$22.58
1D+0.7%
1W-15.4%
1M-22.9%
3M-3.3%
6M-22.9%
YTD-35.3%
1Y-50.2%
ATR %7.8%
52w lowhigh51.7% off high

What CanSino Biologics does

Chinese vaccine maker using viral-vector technology, known for its COVID-19 vaccine and meningitis/rabies/Ebola vaccines.

Most of its non-COVID vaccines are sold on China's voluntary market, where people pay themselves via local disease-control centres rather than through state-funded programmes, so uptake depends on marketing and perceived need. COVID vaccine sales were once large but faded after the pandemic peak. This is the Hong Kong line of a dual-listed company.

In one line: China's viral-vector vaccine player.

Products and services

  • Convidecia (COVID-19 vaccine)
  • Meningococcal vaccines
  • Rabies vaccine
  • Pipeline: Ebola, pertussis vaccines

Customers

  • Governments & health systems (China & export marke

Where it sits in the supply chain

  • Vaccines
  • Viral-vector & recombinant vaccine R&D
  • Manufacturing & distribution

What could go right

  • New vaccine pipeline approvals
  • Export market expansion

What could go wrong

  • Post-COVID demand collapse for legacy vaccine
  • Vaccine pricing/reimbursement pressure

Moat: narrow (IP / patents, regulatory licence). Proprietary viral-vector platform and China vaccine licences, but demand fell sharply post-pandemic.

Headquarters: Tianjin, China · Founded: 2009 · Employees: 1,134

Named competitors

CanSino Biologics at a glance

Size CanSino Biologics (6185.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $1.36B, the 497th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$22.58 on 18 Nov 2026.

Performance Over six months the shares fell 22.9%, against -20.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue grew 36.1% over the last twelve months (peer median +20.3%); the operating margin is -4.0% (peer median -295.1%).

Valuation It trades at 60.5× forward earnings against a peer median of 42.5× (3rd most expensive of 7).

Capital Return on invested capital runs 7.2 points below its cost of capital (9.0% WACC).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012521 May 202621 Aug 202618 Nov 20266185.HK 80Peer median 79
Six months, rebased to 100: CanSino Biologics against the median of its 20 peers (local-currency closes).

CanSino Biologics financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$1.43BHK$1.15BHK$894MHK$381MHK$1.20B
Revenue growth—+28%+134%-68%—
Gross profitHK$1.16BHK$759MHK$505M-HK$1.09B-HK$313M
EBITDAn/aHK$67.9M-HK$217M-HK$2.11B-HK$1.50B
Net incomeHK$34.6MHK$30.2M-HK$411M-HK$1.64B-HK$1.06B
Free cash flow-HK$71.9M-HK$170M-HK$639M-HK$1.72B-HK$3.22B
Capital expenditureHK$181MHK$265MHK$496MHK$675MHK$1.21B
Total debtHK$1.09BHK$1.44BHK$2.14BHK$2.97BHK$3.03B

Quarterly statements and history in the cockpit →

CanSino Biologics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-25%0%+25%+50%NTLA4588TYRARAPPNUVBANABABSINVAXQURE688105688765MSB0870106185.HK6-month return →1-month return →
Up and to the right = strong over both horizons. CanSino Biologics is the large dot.

Fundamentals: revenue growth against valuation

0%+100%0×50×100×ANABNVAX688105URGN26373012076185.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CanSino Biologics is the large dot.

CanSino Biologics competitors and peer comparison

Head to head with its named competitors (6185.HK vs 300122.SZ vs 300142.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
CanSino Biologics 6185.HK$1.36B-23%+36%-4%60.5×n/a
Chongqing Zhifei Biological Products 300122.SZ$5.28B-1%-28%-210%n/a-6.5%
Walvax Biotechnology 300142.SZ$2.48B-26%-23%5%348.7×29.5%

How CanSino Biologics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CanSino Biologics against its 20 peers (data as of 18 Nov 2026)
Measure6185.HKPeer medianRank in peer set
1-month return-22.9%-15.3%3rd lowest of 21
6-month return-22.9%-20.3%8th lowest of 20
Distance from 52-week high-51.7%-48.1%9th lowest of 21
Revenue growth (TTM)+36.1%+20.3%8th highest of 19
Operating margin-4.0%-295.1%3rd highest of 20
Forward P/E60.5×42.5×3rd most expensive of 7
ROIC minus cost of capital-7.2 pp-19.2 pp3rd highest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
CanSino Biologics 6185.HKHong Kong$1.36B-23%+36%-4%60.5×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%n/an/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%n/an/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%n/an/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%n/an/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%n/an/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%4.9×0.5%+25.6%
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%n/an/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%n/an/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%134.6×n/an/a
uniQure QUREUnited States$1.42B-17%+28%-1,027%n/an/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%137.8×39.4%-2.5%
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%n/an/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%n/an/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%n/an/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%16.7×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%46.4×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%n/an/an/a
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%38.6×33.2%-13.1%
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%n/an/an/a

Questions

Who are CanSino Biologics's main competitors?
Named competitors: Sinopharm (China National Biotec) (private or unlisted), Zhifei Biological Products (300122.SZ), Walvax Biotechnology (300142.SZ). The cockpit's measured peer set (industry) also includes Intellia Therapeutics (NTLA), Oncolys BioPharma (4588.T), Tyra Bioscience (TYRA), Rapport Therapeutics (RAPP), Generate Biomedicines (GENB), Nuvation Bio (NUVB).
Is CanSino Biologics expensive compared with its peers?
On forward p/e it trades at 60.5× against a peer median of 42.5×, 3rd most expensive of 7 in its peer set.
How has CanSino Biologics stock performed?
Over six months to 18 Nov 2026 the shares returned -22.9% against -20.3% for the median peer; over one year -50.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.